Global Surgery Policy Unit, LSE Health, The London School of Economics and Political Science, London, UK
Global Anaesthesia, Surgery and Obstetric Collaboration, Newcastle, UK.
BMJ Glob Health. 2024 Oct 3;9(10):e016439. doi: 10.1136/bmjgh-2024-016439.
Cost-effectiveness evidence is a critical tool to support resource allocation decisions. There is growing recognition that the development of benefit packages for surgical care should be guided by such evidence, particularly in resource-constraint settings.
We conducted a systematic review of evidence (Medline, Embase, Global Health, EconLit and grey literature) on the cost-effectiveness of surgery across low-income and middle-income countries published between January 2013 and January 2023. We included studies with minor and major therapeutic surgeries and minimally invasive intraluminal and endovascular interventions. We computed and compared the average cost-effectiveness ratios (ACERs) for different surgical interventions to the respective national gross domestic product per capita to determine cost-effectiveness and to common traditional public health interventions.
We identified 87 unique studies out of 20 070 articles screened. Studies spanned 23 countries, with China (n=20), Thailand (n=12), Brazil (n=8) and Iran (n=8) accounting for about 55% of the evidence. Overall, the median ACERs across procedure groups ranged from I$17/disability-adjusted life year (DALY) for laparotomies to I$170 186/DALY for bariatric surgeries. Most of the ACER estimates were classified as cost-effective (89%) or very cost-effective (76%). Low-complexity surgical interventions compared favourably to common public health interventions.
These findings reinforce the growing body of evidence that investments in surgery are economically smart. There remains however paucity of high-quality evidence that would allow decision-makers to assess the comparative cost-effectiveness of surgery and to determine best buys across a wide range of specialties and interventions. A concerted effort is needed to advance the generation and utilisation of economic evidence in the drive towards scale-up of surgical care across low-income and middle-income countries.
成本效益证据是支持资源分配决策的重要工具。越来越多的人认识到,应根据此类证据制定外科护理福利套餐,特别是在资源有限的情况下。
我们对 2013 年 1 月至 2023 年 1 月期间在中低收入国家发表的关于手术成本效益的证据(Medline、Embase、全球卫生、EconLit 和灰色文献)进行了系统综述。我们纳入了具有小型和大型治疗性手术以及微创腔内和血管内介入的研究。我们计算并比较了不同手术干预措施的平均成本效益比(ACER)与各自国家人均国内生产总值,以确定成本效益,并与常见的传统公共卫生干预措施进行比较。
我们从筛选出的 20070 篇文章中确定了 87 项独特的研究。研究覆盖了 23 个国家,其中中国(n=20)、泰国(n=12)、巴西(n=8)和伊朗(n=8)占证据的 55%左右。总体而言,各手术组的中位数 ACER 从剖腹术的每残疾调整生命年(DALY)17 国际元到减肥手术的每 DALY170186 国际元不等。大多数 ACER 估计值被归类为具有成本效益(89%)或非常具有成本效益(76%)。低复杂性的外科干预措施与常见的公共卫生干预措施相比具有优势。
这些发现强化了越来越多的证据,即对手术的投资具有经济意义。然而,仍然缺乏高质量的证据,使决策者能够评估手术的相对成本效益,并确定在广泛的专业和干预措施中最佳购买方案。需要共同努力,推进经济证据的产生和利用,以推动在中低收入国家扩大外科护理的规模。